Disease Landscape and Forecast Insights

The hepatocellular carcinoma market in China is poised to experience substantial market growth over the 2021-2031 period. In China, even though systemic targeted drugs for hepatocellular carcinoma…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML). Although…

Immune checkpoint inhibitors, such as Merck & Co.’s Keytruda and GlaxoSmithKline’s Jemperli, and targeted therapies, such as Eisai’s Lenvima, have revolutionized the therapeutic landscape of…

China’s psoriasis market has grown significantly over the last few years owing to the growing use of biologics to treat the disease. We expect the market to expand further over the 2021-2031…

Clarivate Epidemiology’s coverage of focal segmental glomerulosclerosis (FSGS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…

Clarivate Epidemiology’s coverage of glomerulonephritis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

The ovarian cancer market in China is poised to experience substantial market growth over the 2021-2031 forecast period. For patients with ovarian cancer, chemotherapy regimens remain the go-to…

The ovarian cancer market in China is poised to experience substantial market growth over the 2021-2031 forecast period. For patients with ovarian cancer, chemotherapy regimens remain the go-to…

Clarivate’s Pharma Industry Report provides pharma executives with a comprehensive summary of the current and future state of the global pharmaceutical industry. Scope This report pulls…

Clarivate Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of glioma for each country, as well…

Clarivate Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of glioma for each country, as well…

Clarivate Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of glioma for each country, as well…